Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential
12:08pm, Monday, 13'th Jan 2025
BioAge Labs and Novartis have formed a strategic partnership to discover age-related therapies, providing BioAge with crucial validation and funding amid Azelaprag's clinical trial failure. Despite Bi
Novartis Entresto® US patent upheld by US Court of Appeals
01:15am, Monday, 13'th Jan 2025
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto® (sacubitril/valsartan) combinati
Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025
04:32pm, Friday, 10'th Jan 2025
Novartis experienced a strong bull run in 2024 but saw a 13% pullback post-Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 p
AI, vaccine distrust, & the future of healthcare: Novartis CEO
10:25am, Friday, 10'th Jan 2025
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
10:02am, Friday, 10'th Jan 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 07'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
02:56pm, Tuesday, 31'st Dec 2024
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
Here's Why Novartis (NVS) is a Strong Growth Stock
11:01am, Tuesday, 31'st Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis gene therapy helps children with rare muscle disorder in study
11:01am, Monday, 30'th Dec 2024
Swiss drugmaker Novartis said on Monday its gene therapy helped improve motor function in children with a rare muscle disorder that leaves patients too weak to walk, talk and swallow.
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
12:45am, Monday, 30'th Dec 2024
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal onase
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules
11:19am, Friday, 27'th Dec 2024
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis
Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near Term
08:50am, Monday, 23'rd Dec 2024
These five laggards of this year have double-digit upside left in the near term. They are: UBER, NVS, RYAAY, OKTA, BAH.
Some 330 jobs hit as Novartis closes Morphosys, WiWo reports
05:21am, Thursday, 19'th Dec 2024
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to a
